FRAX597

Catalog No.S7271 Batch:S727102

Print

Technical Data

Formula

C29H28ClN7OS
Molecular Weight 558.10 CAS No. 1286739-19-2
Solubility (25°C)* In vitro DMSO 24 mg/mL (43.0 mM)
Ethanol 1 mg/mL (1.79 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
Targets
PAK1 [1]
(Cell-free assay)		 PAK2 [1]
(Cell-free assay)		 PAK3 [1]
(Cell-free assay)
8 nM 13 nM 19 nM
In vitro FRAX597 (100 n M) displays a significant inhibitory capacity toward YES1 (87%), RET (82%), CSF1R (91%), TEK (87%), PAK1 (82%), and PAK2 (93%), while displays minimal inhibitory activity towards the group II PAKs: PAK4 (0%), PAK6 (23%), and PAK7 (8%). FRAX597 treatment dramatically impairs the proliferation of Nf2-null SC4 Schwann cells (SC4 cells). FRAX597 displays an IC50 value of 48 nM against wild type PAK1, while IC 50 values against the V342F and V342Y PAK1 mutants are higher than 3μM and 2 μM, respectively.[1] FRAX597 inhibits the proliferation and motility of both benign (Ben-Men1, 3μM) and malignant (KT21-MG1, 0.4 μM) meningiomas cells after treating of 72 h.[2]
In vivo In NOD/SCID mice which bearing Nf2-/-SC4 Schwann cells, FRAX597 (100 mg/kg/day, p.o.) causes more significant tumor growth inhibition cpmpared with control mice.[1] In SCID mice with orthotopic meningioma, FRAX597 (90 mg/kg/day, p.o.) significantly suppresses tumor growth.[2] In KrasG12D mice, treatment with FRAX597 (90 mg/kg/day, p.o.) causes tumor regression and loss of Erk and Akt activity.[3]

Protocol (from reference)

Kinase Assay:[1]
  • Determination of Enzyme IC50 Values

    IC50 values are determined using a 10 concentration point, non-radioactive, functional assay that employs a fluorescence-based, coupled-enzyme format, according to the manufacturer’s protocol (Z’-LYTE@biochemical assay). Kinase selectivity is determined using both the Z’-LYTE@ and Adapta@ kinase assay format.
Cell Assay:[1]
  • Cell lines

    SC4 cells

  • Concentrations

    1 μM

  • Incubation Time

    4 day

  • Method

    30,000 cells/well are plated in 12-well dishes in triplicate. Cell growth media with or without FRAX597 is replaced daily. At indicated time points, cells from individual wells are trypsinized and counted using a Coulter counter.
Animal Study:[2]
  • Animal Models

    SCID mice with orthotopic meningioma model

  • Dosages

    90 mg/kg/day

  • Administration

    p.o.

Customer Product Validation

Data from [Data independently produced by , , Oncotarget, 2016, 7(15):19709-22]

Data from [Data independently produced by , , Am J Cancer Res, 2017, 7(8):1724-1737]

Data from [Data independently produced by , , PLoS One, 2016, 11(9):e0162214]

Selleck's FRAX597 has been cited by 36 publications

Targeting endothelial PDGFR-β facilitates angiogenesis-associated bone formation through the PAK1/NICD axis [ J Cell Physiol, 2024, 10.1002/jcp.31291] PubMed: 38721633
VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma [ Sci Rep, 2024, 14(1):4060] PubMed: 38374399
TRIM40 is a pathogenic driver of inflammatory bowel disease subverting intestinal barrier integrity [ Nat Commun, 2023, 14(1):700] PubMed: 36755029
Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer [ J Exp Clin Cancer Res, 2023, 42(1):56] PubMed: 36869386
Neutrophil Extracellular Traps Delay Diabetic Wound Healing by Inducing Endothelial-to-Mesenchymal Transition via the Hippo pathway [ Int J Biol Sci, 2023, 19(1):347-361] PubMed: 36594092
Neutrophil Extracellular Traps Delay Diabetic Wound Healing by Inducing Endothelial-to-Mesenchymal Transition via the Hippo pathway [ Int J Biol Sci, 2023, 19(1):347-361] PubMed: 36594092
ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1 [ Cell Commun Signal, 2023, 21(1):193] PubMed: 37537668
Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma [ Blood Sci, 2023, 5(4):249-257] PubMed: 37941919
Targetable leukemia dependency on noncanonical PI3Kγ signaling [ bioRxiv, 2023, 10.1101/2023.12.15.571909] PubMed: none
Phosphoproteomic profiling of influenza virus entry reveals infection-triggered filopodia induction counteracted by dynamic cortactin phosphorylation [ Cell Rep, 2022, 38(4):110306] PubMed: 35081340

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.